AEON Biopharma, Inc. (AEON)
NYSEAMERICAN: AEON · IEX Real-Time Price · USD
2.250
-0.310 (-12.11%)
At close: Jul 19, 2024, 4:00 PM
2.340
+0.090 (4.00%)
Pre-market: Jul 22, 2024, 7:38 AM EDT
AEON Biopharma Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for AEON Biopharma stock has a target of 6.00, which predicts an increase of 166.67% from the current stock price of 2.25.
Analyst Consensus: Strong Buy
Analyst Ratings
According to 1 stock analyst, the rating for AEON Biopharma is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +166.67% | Jul 10, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +166.67% | May 30, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $18 → $6 | Strong Buy | Maintains | $18 → $6 | +166.67% | May 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +700.00% | May 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +700.00% | Apr 17, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.57
from -8.72
EPS Next Year
-3.88
from -1.57
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 24.8M | 2.5M | 92.4M |
| Avg | n/a | n/a | 24.1M | 2.4M | 89.7M |
| Low | n/a | n/a | 23.2M | 2.3M | 86.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | -89.7% | 3,736.9% |
| Avg | - | - | - | -90.0% | 3,627.2% |
| Low | - | - | - | -90.4% | 3,481.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.99 | -0.91 | -1.10 | -0.57 | 0.19 |
| Avg | -3.88 | -0.89 | -1.07 | -0.55 | 0.18 |
| Low | -3.72 | -0.85 | -1.03 | -0.53 | 0.18 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.